

2005

# **Metabolic syndrome and IMT: A community study in adult Koreans**

Jeong Seul-Ki, M.D.

---

**Department of Neurology  
Chonbuk National University Hospital**

- Stroke in diabetics
  - Overview
  - Pathophysiology
- IMT as a surrogate marker of atherosclerosis in the metabolic syndrome
  - Namwon study
- Conclusion

# Stroke in diabetics

## 1. Type 2 DM: A strong independent risk factor for stroke

A risk factor for stroke, according to Framingham & other studies.


A consistent **2–5 fold increase** in stroke incidence in diabetes

In the stroke population younger than 55 years ( **55 years**),  
diabetes increases the risk of stroke more than 10-fold  
(**OR 11.6**, 95% CI 1.2-115.2)

*You RX. Stroke 1997;28;1913-1918*

# Stroke in diabetics

## Stroke incidence and fasting blood glucose, diabetes



*Burchfiel CM. Stroke 1994;25:951*

# Stroke in diabetics (pathophysiology)

## 2. Pathophysiologic mechanisms of diabetic angiopathy

### 1) Changes in arterial wall (atherosclerosis)

#### abnormal endothelium

Diabetes mellitus — abnormal endothelium

Function	Mechanism	Abnormality	Result
Permeability barrier	Tight cell junctions	↑ permeability—delayed regeneration	LDL, mitogens subendothelial
Thromboresistant surface	NO, PGI <sub>2</sub> , t-PA, heparan [spelling?] sulfate thrombomodulin	↓ NO, ↓ PGI <sub>2</sub> , ↑ PAI-1, ↑ TF	Enhanced impaired
Block leukocyte adherence	NO	Induction of adhesion molecules (VCAM-1, E-selectin)	Recruitment macrophages to vascular
Regulation of vascular tone	NO, PGI <sub>2</sub> , bradykinin ET-1, AT-II	↓ NO, PGI <sub>2</sub> , bradykinin; ↑ ET-1, AT-II; ↑ AGEs	Impaired vasodilation
Secrete growth inhibitors/cytokines	NO, heparan sulfate, IL-6, TNF	Inactivation of NO, C-reactive protein	↑ VSMC proliferative activity, ↑ inflammation

# Stroke in diabetics (pathophysiology)

## 2) Hyper-coagulability

Alteration in coagulation, fibrinolysis, and platelet function in DM.

- Clotting abnormality

(antithrombin and protein C deficiency, activated intrinsic pathway)

- Reduced fibrinolysis (elevated plasminogen activator inhibitor-1)

- Platelet dysfunction

(platelet vessel wall interaction, platelet-platelet interaction, platelet secretion, platelet-coagulant protein interaction)

## 3) Changes in blood flow

- Increased fibrinogen & globulins → increase blood viscosity → low flow.

- Poor collateral circulation

- Chronic impairment of auto-regulation.

# Stroke in diabetics

## 2. More severe stroke and more frequent worsening

### *Elevated glucose in acute stage:*

- Determinant of initial infarct volume & early infarct progression (esp. non-lacunar stroke).

### The mechanisms of the deleterious effects of hyperglycemia


- The production of **lactic acid** from glucose under hypoxic conditions  
→ cerebral intra- and extra-cellular acidosis → damage to neurons, glial cells
- Hyperglycemia **inhibit the reuptake of the neurotransmitters**: glutamate and aspartate  
→ may eventually cause neuronal death.
- The development of **intracranial atheroma** in large, medium and small arteries  
→ poor collateral circulation, impaired auto-regulation.

*Lindsberg PJ. Stroke 2004;35:363-364*


# Stroke in diabetics

The deleterious influence of acute hyperglycemia

1. On penumbral tissue
2. Due to increased tissue lactate production.



In patients with an acute PWI > DWI mismatch, increasing blood glucose levels  
→ reduced penumbral salvage,  
larger final infarct size,  
worse clinical outcome.



Parsons MW, *Ann Neurol* 2002;52:20-28



# Stroke in diabetics

## 4. A higher frequency of recurrent stroke

*Olsson T, et al. (1990)*

People with diabetes may also be more likely to suffer recurrent stroke  
(**24% vs. 17%**)

*Hier DB, et al. (1996)*

Higher frequency of recurrent stroke in diabetic stroke population compared to non-diabetic population (**15.2% vs. 11.4% / 2yr**)

*Statton IM, et al. (2000) [UKPDS study]*

A 12% reduction in the hazard ratio for fatal & non-fatal stroke per 1% decrease in HbA1c (**12% reduction / 1% decrease of HbA1c**)

# Stroke in diabetics

## 5. Predictor of poor outcome

- **Mortality**

- Systematic overview of 33 studies: Hyperglycemia on admission – associated with **3-fold risk** of fatal 30-day outcome and **1.4-fold risk** of poor functional outcome

*Stroke 2004;35:363-364*

- **Hemorrhagic transformation of ischemic stroke**

Patients with an initial s-glucose > 200mg/dl or a known diabetes had a symptomatic hemorrhage (following rtPA administration): **25% vs. 9%**

*Demchuk AM, Stroke 1999;30:34-39*

As the admission glucose increased, the odds for symptomatic ICH also increased (**OR 1.75** per 100 mg/dL increase in s-glucose,  $p=0.02$ ).

*The NINDS rt-PA study group, Stroke 1997 & Neurology 2002*



## Metabolic syndrome and IMT

- Is IMT a good surrogate marker of atherosclerosis in the metabolic syndrome, a preclinical state of type 2 diabetes mellitus?

# Subjects & methods

- Since 2004, 4715 + 1620 participants in community
- Major variables
  - Age, sex, education, past history, anthropometry, K-mMMSE, BMD, PFT, Chest PA, etc
  - Resting BP, IMT, ABI, Arterial stiffness, EKG, etc
- Namwon Stroke Registry (NSR)
- samples
  - Plasma, serum, urine, DNA, Buffy coat

# Subjects & methods

## Carotid IMT

- More than 20 clinical trial and observational studies :  
carotid IMT as a primary end point.

Pauciullo P. *Arterioscler Thromb.* 1994;14:1075-79

- Increased carotid IMT is a better predictor of **stroke** than of  
ischemic heart disease and myocardial infarction (MI).

Ebrahim S. *Stroke* 1999;30:841–850.  
Bots ML. *Circulation* 1997;96:1432–1437.

# Subjects & methods

## IMT measurement



- Neck Duplex Sonography
- B-mode imaging & Color Flow Imaging(CFI)
- SonoAce-9900, Medison Co., Korea
- 4-7 MHz linear probe
- Angle correction (60°)
- Anterior or Anterolateral approach
- Maximal thickness (CCA, carotid bulb, ICA)
- SigmaScan<sup>®</sup> Pro 5.0

# Definition: IMT

First interface ; *lumen-intima*

Second interface ; *media-adventitia*

**IMT**



Schmidt-Trucksass A. Atherosclerosis 2003;166:57-65

ARIC (Atherosclerosis Risk In Community) study



# Definition: Metabolic syndrome

## PAPER

### Metabolic syndrome and ALT: a community study in adult Koreans

S-K Jeong<sup>1\*</sup>, H-S Nam<sup>2</sup>, J-A Rhee<sup>3</sup>, J-H Shin<sup>3</sup>, J-M Kim<sup>4</sup> and K-H Cho<sup>5</sup>

<sup>1</sup>Department of Neurology, Seonam University School of Medicine, Seonam University School of Medicine, Gwangju University School of Medicine, Gwangju University School of Medicine, Gwangju-city, South Korea; and <sup>5</sup>Department of Internal Medicine, Seoul National University School of Medicine, Seoul, Korea

**OBJECTIVE:** To investigate an association between metabolic syndrome and alanine aminotransferase (ALT) levels in a community-based study.

**DESIGN:** A population-based cross-sectional study.

**SUBJECTS:** A total of 1248 men and 213 women.

**MEASUREMENTS:** Body mass index (BMI), waist circumference, blood pressure, fasting glucose, and ALT.

**RESULTS:** ALT and BMI increased with increasing waist circumference. The MS was found in both sexes, and the prevalence was higher in the high waist circumference group.

**CONCLUSION:** The MS is significantly associated with ALT levels. The MS is a sensitive marker of hepatic dysfunction.

*International Journal of Obesity* (2004) 28, 1111-1116

Published online 15 June 2004

**Keywords:** metabolic syndrome; alanine aminotransferase

#### Definition

The MS was identified by the presence of three or more of the components, according to the Third Adults Treatment Panel (ATP-III) of the National Cholesterol Education Program (NCEP),<sup>18</sup> modified to use different waist circumference cutoffs instead of the original:<sup>19</sup>

- (1) abdominal obesity: waist circumference  $\geq 90$  cm in men and  $\geq 80$  cm in women;
- (2) high triglyceride:  $\geq 1.695$  mmol/l;
- (3) low HDL cholesterol:  $< 1.036$  mmol/l in men and  $< 1.295$  mmol/l in women;
- (4) high blood pressure:  $\geq 130/85$  mmHg or subjects using antihypertensives;
- (5) high fasting glucose:  $\geq 6.1$  mmol/l.

# Analysis

- Independent t-test
- Analysis of variance (ANOVA)

# Results-1

- 2004. 7~8.
- 20-74 , 1620

- Age: mean  $\pm$  SD,  $53.4 \pm 14.4$  y  
(men,  $54.5 \pm 14.4$  y; women,  $52.5 \pm 14.3$  y)
- Sex: women, 53.7%

# Results-2

- MS: 346 (22.1%)

- Its Components:


- 1, 338 (21.6%)
- 2, 480 (31.3%)
- 3, 231 (14.8%)
- 4, 91 ( 5.8%)
- 5, 24 ( 1.5%)

- MS according to age group

- age < 40, 7.4%
- 40 age < 60, 19.5%
- age 60, 30.2%


# Results-3

Figure 1. IMT and the metabolic syndrome




# Results-3

Figure 2. IMT and the MS component, FBS 110 mg/dl




# Results-3

Figure 3. IMT and the MS component, high BP



# Results-3


Figure 4. IMT and the MS component, abdominal obesity





# Results-3

Figure 5. IMT and the MS component, low HDL cholesterol



# Results-3

Figure 6. IMT and the MS component, high TG





Figure 7. IMT according to summation of MS components



# Discussion

- IMT value was significantly higher in the participants with the metabolic syndrome than the normal participants
- Among the components, high BP and FBS were significantly associated with higher IMT values
- According to the summation of the components, IMT values were significantly increased in all the six carotid artery segments

# Discussion

- Is IMT a good surrogate marker of **atherosclerosis** in the metabolic syndrome, a preclinical state of type 2 DM?
  - Biomarker (surrogate ??): a measurement that is indicative of a pharmacodynamic response (PD) to a therapeutic intervention (dose, PK)
  - Five attributes of an ideal biomarker
    - Pathophysiologic relevance
    - Accurately and reproducibly quantified
    - Modified by drug exposure
    - Sensitivity and specificity to drug effects
    - Predictive value

# Discussion

- Is IMT a good surrogate marker of **atherosclerosis** in the metabolic syndrome, a preclinical state of type 2 DM?
  - Surrogate markers in DM and the metabolic syndrome and in evaluating lipid-lowering therapy; conventional and contrast enhanced carotid IMT
    - Rajaram V. et al. Am J Cardiol 2004;93:32C-48C
  - Carotid IMT significantly decreased one year after remission of Cushing's syndrome
    - Faggiano A. et al. J Clin Endocrinol Metab 2003;88:2527-33
  - Endothelial activation do not associate with IMT
    - Leinonen ES. et al. J Intern Med 2004;256:110-27

# Discussion

- Surrogate markers of the metabolic syndrome, more!

